Exicure, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $2.4 million, compared to a loss of $1.1 million in the same period last year. The company did not generate any revenue during the quarter, maintaining a total revenue of $0 for both the three and nine months ended September 30, 2025, a significant decline from $500,000 reported for the nine months ended September 30, 2024. The operating loss for the quarter was $2.4 million, slightly improved from a loss of $2.6 million in the prior year, reflecting a 7% decrease in total operating expenses, which amounted to $2.4 million compared to $2.6 million in Q3 2024.
The company’s financial position has changed notably since the previous fiscal period. As of September 30, 2025, Exicure's cash and cash equivalents stood at $4.4 million, a decrease from $12.5 million at the end of 2024. The total assets increased slightly to $15.3 million from $15.1 million, while total liabilities also rose to $8.3 million from $8.3 million. The company’s accumulated deficit grew to $201.3 million, up from $199.3 million at the end of 2024. The increase in operating expenses was primarily driven by research and development costs of $0.9 million, reflecting the resumption of R&D activities following the acquisition of GPCR USA.
Strategically, Exicure has made significant moves, including the acquisition of GPCR Therapeutics USA Inc. in January 2025, which has allowed the company to re-enter the clinical development space. This acquisition is expected to enhance Exicure's capabilities in developing therapies for blood cancer patients. The company also formed a new subsidiary, KC Creation Co., Ltd., in South Korea, aimed at exploring collaborations and diversifying its business model. The ongoing Phase 2 clinical trial involving GPC-100, a treatment for Multiple Myeloma, is a key operational focus, with results expected in the fourth quarter of 2025.
Despite these developments, Exicure faces substantial challenges, including a lack of recurring revenue and the need for additional capital to sustain operations. The company has expressed doubt about its ability to continue as a going concern without securing further financing. Management is exploring various strategic alternatives, including potential partnerships and capital raises, but acknowledges the difficulty in obtaining funding given the current market conditions and the company's financial status. The outlook remains uncertain, with the company emphasizing the need for immediate action to secure its financial future.
About EXICURE, INC.
Exicure, Inc. is a biotechnology company focused on developing nucleic acid therapies targeting RNA. It has historically worked on spherical nucleic acid (SNA) technology for therapeutic applications but has shifted to exploring strategic transactions and asset sales. The company owns a patent portfolio, engages in licensing, and seeks growth through acquisitions and partnerships, primarily in Asia, with no current revenue stream or manufacturing operations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.